Lipton, J.H., Bryden, P., Sidhu, M.K., Huang, H., McGarry, L.J., Lustgarten, S., Mealing, S., Woods, B., Whelan, J. and Hawkins, N. (2015) Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Leukemia Research, 39(1), pp. 58-64. (doi: 10.1016/j.leukres.2014.10.005) (PMID:25466286)
Full text not currently available from Enlighten.
Abstract
We compared the efficacy of ponatinib and second-generation tyrosine kinase inhibitors (2G-TKIs: bosutinib, dasatinib, and nilotinib) in chronic phase CML resistant/intolerant to ≥1 prior 2G-TKI. Estimated probabilities of CCyR with 2G-TKI ranged from 22% to 26%, compared with 60% (95% CrI 52–68%) with ponatinib. The estimated probability of ponatinib providing higher response rate than all other included treatments was 99% (CCyR) and 97% (MCyR). Use of further 2G-TKI may provide limited benefit in CP-CML patients resistant/intolerant to prior 2G-TKI treatment. Compared with 2G-TKIs, ponatinib is estimated to provide substantially higher probability of achieving CCyR and MCyR; safety was not compared.
Item Type: | Articles |
---|---|
Additional Information: | Research funding for this analysis was provided by ARIAD Pharmaceuticals, Inc. |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Hawkins, Professor Neil |
Authors: | Lipton, J.H., Bryden, P., Sidhu, M.K., Huang, H., McGarry, L.J., Lustgarten, S., Mealing, S., Woods, B., Whelan, J., and Hawkins, N. |
College/School: | College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Health Economics and Health Technology Assessment |
Journal Name: | Leukemia Research |
Publisher: | Elsevier |
ISSN: | 0145-2126 |
ISSN (Online): | 0145-2126 |
Published Online: | 01 November 2014 |
University Staff: Request a correction | Enlighten Editors: Update this record